Adjuvants

References

• Edelman R. Vaccine adjuvants. Rev. Infect. Dis 1980; 2: 370–383
   PubMedGoogle Scholar
• Allison A. C., Byars N. E., Waters R. V. (1984) Immunological adjuvants: Efficacy and safety considerations. New Approaches to Vaccine Development. Proceedings of a Meeting Organized by the World Health Organization in Geneva. 17–20 October, 1983, R. Bell, G. Tarrigiani. World Health Organization, Schwabe and Co. A.G., Geneva, BaselSwitzerland
   Google Scholar
• Warren H. S., Vogel F. R., Chedid L. A. Current status of immunological adjuvants. Ann. Rev. Immunol 1986; 4: 369–388
   PubMed Web of Science ®Google Scholar
• Warren H. S., Chedid L. A. Future prospects for vaccine adjuvants. CRC Crit. Rev. Immunol 1988; 8: 83–101
   Google Scholar
• Ramon G. Precedes pour accroitre la production des antitoxines. Ann. Inst. Pasteur 1926; 40: 1–10
   Google Scholar
• Brown F. From Jenner to genes-the new vaccines. Lancet 1990; 335: 587–590
   Google Scholar
• Milich D. R. Synthetic T and B recognition sites: Implications for vaccine development. Adv. Immunol 1989; 45: 195–282
   PubMed Web of Science ®Google Scholar
• Allison A. C. Macrophage activation and nonspecific immunity. Int. Rev. Exp. Pathol 1978; 18: 303–346
   PubMedGoogle Scholar
• Allison A. C., Byars N. E. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. J. Immunol. Methods 1986; 95: 157–168
   PubMed Web of Science ®Google Scholar
• Ribi E. Advances in Carriers and Adjuvants for Veterinary Biologies, R. M. E NervigM. Gough, M. L. Kaeherle, C. A. Whetstone. Iowa State University Press, Ames, lA 1986; 35
   Google Scholar
• Jolivet J., Sache E., Audibert E. Biological studies of lipophilic MDP derivatives incorporated into liposomes. Immunol. Commun 1981; 10: 511–522
   PubMed Web of Science ®Google Scholar
• Chedid L., Audibert E., Johnson A. G. Biological activities of muramyl dipeptide, a synthetic glycopeptide analogous to bacterial immunoregulating agents. Prog. Allergy 1978; 25: 63–105
   Google Scholar
• Telzak E., Wolff S. M., Dinarello C. A., et al. Clinical evaluation of the immunoadjuvantmurabutide, a derivative of MDR administered with a tetanus toxoid vaccine. J. Infect. Dis 1986; 153: 628–633
   Google Scholar
• Byars N. E., Allison A. D. Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity. Vaccine 1987; 5: 223–228
   PubMed Web of Science ®Google Scholar
• Morein B., Sundquist B., Hoglund S., et al. ISCOMS, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 1984; 308: 457–460
   PubMed Web of Science ®Google Scholar
• Morein B. The iscom antigen-presenting system. Nature 1988; 332: 287–288
   PubMed Web of Science ®Google Scholar
• Osterhaus A., Weijer K., UytdeHaag E., et al. Serological responses in cats vaccinated with FeLV ISCOM and an inactivated FeLV vaccine. Vaccine 1989; 7: 137–141
   Google Scholar
• Pyle S. W., Morein B., Bess J. W., Jr., et al. Immune response to immunostimulatory complexes (ISCOMs) prepared from human immunodeficiency virus type 1 (HIV-I) or the HIV-1 external envelope glycoprotein (gpl20). Vaccine 1989; 7: 465–473
   PubMedGoogle Scholar
• Johnson A. G., Gaines S., Landy M. Studies on the O antigen of Salmonella typhosa. V. Enhancement of the antibody response to protein antigens by the purified lipopolysaccharide. J. Exp. Med 1956; 103: 225–246
   PubMed Web of Science ®Google Scholar
• Ohta M., Nakashima I., Kato N. Adjuvant action of bacterial lipopolysaccharide in induction of delayed-type hypersensitivity to protein antigens. 11. Relationships of intensity of the action to that of other immunological activities. Immunobiology 1982; 163: 460–469
   PubMed Web of Science ®Google Scholar
• Ribi E., Cantrell J. L., Takayama K., Querishi N., Peterson J., Ribi H. O. Lipid A and immunotherapy. Rev. Infect. Dis 1984; 6: 567–572
   PubMedGoogle Scholar
• Chiller J. M., Skidmore B. J., Morrison D. C., Weigle W. O. Relationship of the structure of bacterial lipopolysaccharides to its function in mitogenesis and adjuvanticity. Proc. Natl. Acad. Sci. USA 1973; 70: 2129–2133
   Google Scholar
• Tanamoto K., Zahringer U., McKenzie G. R., Galanos C., Rietschel E. T., Luderitz O., Kusumoto S., Shiba T. Biological activities of synthetic lipid A analogs: pyrogenicity, lethal toxicity, anti-complement activity, and induction of gelatin of Limulus amoebocyte lysate. Infect. Immun 1984; 44: 421–426
   Google Scholar
• Kotani S., Takada H., Tsujimoto J., Ogawa T., Harada K., Mori Y., Kawasaki A., Tanaka A., Nagao S., Tanaka S., Shiba T., Kusumoto S., Imoto M., Yoshimura H., Yamamoto M., Shimamoto T. Immunologically active lipid A. analogues synthesized according to a revised structural model of natural lipid A. Infect. Immun 1984; 45: 293–296
   PubMed Web of Science ®Google Scholar
• Myers K. R., Welty D. M., Ulrich J. T. The immunological adjuvant activity of liposomes containing monophosphoryl lipid A and a synthetic analog of trehalose dimycolate. FASEB J 1989; 3: A605
   Google Scholar
• Geerlings H. J., Weijer W. J., Welling G. W., Welling-Wester S. The influence of different adjuvants on the immune response to a synthetic peptide comprising amino acid residues 9–21 of herpes simplex virus type 1 glycoprotein D. J. Immunol. Methods 1989; 124: 95–102
   Google Scholar
• Mitchell M. S., Kan-Mitchell J., Kempf R. A., et al. Active specific immunotherapy for melanoma; phase I trial of allogenic lysates and a novel adjuvant. Cancer Res 1988; 48: 5338–5893
   Google Scholar
• Nunberg J. H., Doyle M. V., York S. M., York C. J. Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine. Proc. Natl. Acad. Sci. USA 1989; 86: 4240–4243
   PubMed Web of Science ®Google Scholar
• Perrin P., Joffret J. L., Leclerc C., Oth D., Sureau P., Thibodeau L. Interleukin 2 increases protection against experimental rabies. Immunobiol 1988; 177: 199–209
   Google Scholar
• Good M. E., Pombo D., Lunde M. N., Maloy W. L., Halenbeck R., Koths K., Miller L. H., Berzofsky J. A. Recombinant human IL-2 overcomes genetic nonresponsiveness to malaria sporozoite peptides. Correlation of effect with biologic activity of IL-2. J. Immunol 1988; 141: 972–977
   PubMed Web of Science ®Google Scholar
• Weinberg A., Merigan T. C. Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines. J./ Immunol 1988; 140: 294–299
   PubMed Web of Science ®Google Scholar
• Anderson G., Urban O., Fedorka-Cray E., Newell A., Nunberg J., Doyle M. Interleukin-2 and protective immunity in Haemophilus pleuropneumoniae, preliminary studies. Vaccines 89. Modern Approaches to New Vaccines: Prevention of AIDS and Other Viral, Bacterial, and Parasitic Diseases, R. M. Chanock, R. A. Lerner, F Brown, H. Ginsberg. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 1987; 22–25
   Google Scholar
• Meuer S. C., Dumann H., zum Buschenfelde K. -H. M., Kohler H. Low-dose interleukin-2 induces systemic immune responses against hepatitis B surface antigen in immunodeficient non-responders to hepatitis B vaccine. Lancet 1989; i: 15–17
   Google Scholar
• Fauci A. S., Rosenberg S. A., Sherwin S. A., Dinarello C. A., Longo D. L., Lane H. C. Immunomodulators in clinical medicine. Ann. Intern. Med 1987; 106: 421–433
   PubMed Web of Science ®Google Scholar
• Dinarello C. A. Interleukin-1. Rev. Infect. Dis 1984; 6: 51–95
   PubMedGoogle Scholar
• Staruch M. J., Wood D. D. The adjuvanticity of interleukin 1 in vivo. J. Immunol 1983; 130: 2191–2194
   PubMed Web of Science ®Google Scholar
• Antoni G., Presentini R., Perin E., Tagliabue A., Ghiara R., Censini S., Volpini G., Villa L., Boraschi D. A. short synthetic peptide fragment of human interleukin 1 with immunostimulatory but not inflammatory activity. J. Immunol 1986; 137: 3201–3204
   PubMed Web of Science ®Google Scholar
• March C. J., Mosley B., Larsen A., Cerretti D. P., Braedt G., Price V., Gillis S., Henney C. S., Kronheim S. R., Grabstein K., Conlon P. J., Hopp T. P., Cosman D. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature 1985; 315: 641–647
   PubMed Web of Science ®Google Scholar
• Heath A. W., Devey M. E., Brown I. N., Richards C. E., Playfair J. H. L. Interferon-gamma as an adjuvant in immunocompromised mice. Immunology 1989; 67: 520–524
   PubMed Web of Science ®Google Scholar
• Playfair J. H. L., De Souza J. B. Recombinant gamma interferon is a potent adjuvant for a malaria vaccine in mice. Clin. Exp. Immunol 1987; 67: 5–10
   PubMed Web of Science ®Google Scholar
• Sturchler D., Berger R., Etlinger H., Fernex M., Matile H., Pink R., Schlumbom V., Just M. Effects of interferons on immune response to a synthetic peptide malaria sporozoite vaccine in non-immune adults. Vaccine 1989; 7: 457–461
   PubMed Web of Science ®Google Scholar
• Rajewsky K., Schirmacher V., Nase S., Jerne N. K. The requirement of more than one antigenic determinant for immunogenicity. J. Exp. Med 1969; 129: 1131–1143
   PubMed Web of Science ®Google Scholar
• Mitchison N. A. The carrier effect in the secondary response to hapten-protein conjugates. I. Measurement of the effect with transferred cells and objections to the local environment hypothesis. Eur. J. Immunol 1971; 1: 10–17
   PubMedGoogle Scholar
• Herzenberg L. A., Tokuhisa T., Herzenberg L. A. Carrier-priming leads to hapten-specific suppression. Nature 1980; 285: A-(i61
   Google Scholar
• Herzenberg L. A., Kokuhisa T. Epitopic-specific regulation. I. Carrier-specific induction of suppression for IgG anti-hapten antibody responses. J. Exp. Med 1982; 144: 1730–1740
   Google Scholar
• Schutze M. -P, Leclerc C., Jolivet M., Audibert E., Chedid L. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J. Immunol 1985; 135: 2319–2322
   PubMed Web of Science ®Google Scholar
• Lise L. A., Mazier D., Jolivet X., Audibert R., Chedid L., Schlesinger D. Enhanced epitopic response to a synthetic human malarial peptide by preimmunization with tetanus toxoid carrier. Infect. Immun 1987; 55: 2658–2661
   Google Scholar
• DiJohn D., Wasserman S. S., Torres J. R., Cortesia M. J., Murillo J., Losonsky G. A., Herrington D. A., Sturcher D., Levine M. M. Effect of priming with carrier on response to conjugate vaccine. Lancet 1989; 2: 1415–1418
   Google Scholar
• Vogel E. R., Leclerc C., Schultz M. R., Jolivet M., Audibert F., Klein T. W., Chedid L. Modulation of carrier-induced epitopic suppression by Bordetella pertussis components and muramyl peptide. Cell. Immunol 1987; 107: 40–51
   Google Scholar
• Elson C. O., Balding W. Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J. Immunol 1984; 132: 2736–2741
   PubMed Web of Science ®Google Scholar
• McKenzie S. J., Halsey J. E. Cholera toxin B subunit as a carrier protein to stimulate a mucosal immune response. J. Immunol 1984; 133: 1818–1824
   PubMed Web of Science ®Google Scholar
• Tamura S., Hideki K., Funato H. Protection against influenza virus infection by a two-dose regimen of nasal vaccination using vaccines combined with cholera toxin B subunit. Vaccine 1989; 7: 314–320
   PubMed Web of Science ®Google Scholar
• Elson C. O., Ealding W. Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. J. Immunol 1984; 133: 2892–2897
   PubMed Web of Science ®Google Scholar
• Czerkinsky C., Russell M. W., Lycke N., Lindblad M., Holmgren J. Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues. Infect. Immunol 1989; 57: 1072–1077
   PubMed Web of Science ®Google Scholar
• Liang X., Lamm M. E., Nedrud J. G. Oral administration of cholera toxin-sendai virus conjugate potentiates gut and respiratory immunity against sendai virus. J. Immunol 1988; 141: 1495–1501
   PubMedGoogle Scholar
• Elson C. O. Cholera toxin and its subunits as potential oral adjuvants. Curr. Topics Microbiol. Immunol 1989; 146: 29–33
   Google Scholar
• Jacobs W. R., Tuckman M., Bloom B. R. Introduction of foreign DNA into mycobacteria using a shuttle plasmid. Nature 1987; 327: 532–536
   PubMed Web of Science ®Google Scholar
• Dewar R. L., Natarajan V., Vasudevachari M. B., et al. Synthesis and processing of human immunodeficiency virus type 1 envelope proteins encoded by a recombinant human adenovirus. J. Virol 1989; 63: 129–136
   Google Scholar
• Evans D. J., McKeating J., Meredith J. M., Burke K. L., Katrak K., John A., Ferguson M., Minor P. D., Weiss R. A., Almond J. W. An engineered poliovirus chimaera elicits broadly reactive HIV-I neutralizing antibodies. Nature 1989; 339: 385–388
   PubMed Web of Science ®Google Scholar
• Mackett M., Smith G. L., Moss B. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J. Virol 1984; 49: 857–864
   PubMed Web of Science ®Google Scholar
• Wahdan M. H., Serie C., Cerisier Y., Sallam S., Germanier R. A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results. J. Infect. Dis 1982; 145: 292–295
   PubMed Web of Science ®Google Scholar
• Levine M. M., Ferreccio C., Black R. E., Germanier R., Chilean Typhoid Committee. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet 1987; I: 1049–1052
   Google Scholar
• Black R. E., Levine M. M., Clements M. L., Losonsky G., Herrington D., Berman S., Formal S. B. Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine. J. Infect. Dis 1987; 155: 1260–1265
   PubMedGoogle Scholar
• Tacket C. O., Forrest B., Morona R., Attridge S. R., LaBrooy J., Tall B. D., Reymann M., Rowley D., Levine M. M. Safety, immunogenicity, and efficacy against cholera challenge in man of a typhoid-cholera hybrid vaccine derived from 5. typhi Ty21a. Infect. Immun 1990; 58: 1620–1627
   PubMed Web of Science ®Google Scholar
• Curtiss R., III, Kelly S. M. Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. Infect. Immun 1987; 55: 3035–3043
   PubMed Web of Science ®Google Scholar
• Hoiseth S., Stocker B. A. D. Aromatic-dependent 5a/mone//a fyp/iimHn'um are non-virulent and effective as live vaccines. Nature 1981; 291: 238–239
   PubMed Web of Science ®Google Scholar
• Robertsson J. A., Lindberg A. A., Hoiseth S., Stocker B. A. D. Salmonella typhimurium infection in calves: protection and survival of virulent challenge bacteria after immunization with live or inactivated vaccines. Infect. Immun 1983; 41: 742–750
   PubMed Web of Science ®Google Scholar
• Lindberg A. A., Robertsson J. A. Salmonella typhimurium infection in calves: cell-mediated and humoral immune reactions before and after challenge with live virulent bacteria in calves given live or inactivated vaccines. Infect. Immun 1983; 41: 751–757
   PubMed Web of Science ®Google Scholar
• Smith B. R., Reina-Guerra M., Hoiseth S., Stocker B. A. D., Habasha F., Johnson E., Merritt F. Aromatic-dependent Salmonella typhimurium as modified live vaccines for calves. Am. J. Vet. Med. Res 1984; 45: 59–66
   PubMed Web of Science ®Google Scholar
• Dougan G., Charfield S., Pickard D., Bester J., O'Callaghan D., Maskell D. Construction and characterization of salmonella vaccine strains harboring mutations in two different aro genes. J. Infect. Dis 1988; 158: 1329–1335
   Google Scholar
• Gregoriadis G., Davis D., Davies A. Liposomes as immunological adjuvants: antigen incorporation studies. Vaccine 1987; 5: 145–151
   PubMed Web of Science ®Google Scholar
• Alving C. R., Richards R. L., Moss J., et al. Effectiveness of liposomes as potential carriers of vaccines: applications to cholera toxin and human malaria sporozoite antigen. Vaccine 1986; 4: 166–172
   PubMed Web of Science ®Google Scholar
• Allison A. C., Gregoriadis S. Liposomes as immunological adjuvants. Nature 1974; 252: 252
   PubMed Web of Science ®Google Scholar
• Eldridge J. H., Gilley R. M., Staas I. K., et al. Biodegradable microspheres: vaccine delivery system for oral immunization. Curr. Topics Microbiol. Immunol 1989; 146: 59–66
   Google Scholar
• Moldoveanu Z., Staas J. K., Gilley R. M., et al. Immune responses to influenza virus in orally and systemically immunized mice. Curr. Topics Microbiol. Immunol 1989; 146: 91–99
   Google Scholar
• Arthur L. O., Pyle S. W., Nara P. L., Bess J. W., Jr., Gonda M. A., Kelliher J. C., Gilden R. V., Robey W. G., Bolognesi D. P., Gallo R. C., Fischinger P. J. Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gpl20) subunit vaccine. Proc. Natl. Acad. Sci. USA 1987; 84: 8583–8587
   Google Scholar
• Herman P. W., Groopman J. E., Gregory X., Clapham P. R., Weiss R. A., Ferriani R., Riddle L., Shimasaki C., Lucas C., Lasky L. A., Eichberg J. W. Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gpl20. Proc. Natl. Acad. Sci. USA 1988; 85: 5200–5204
   Google Scholar
• Marx P. A., Pedersen N. C., Lerche N. W., Osborn K. G., Lowenstine L. J., Lackner A. A., Maul D. H., Kwang H. -S., Kluge J. D., Zaiss C. P., Sharpe V., Spinner A. P., Allison A. C., Gardner M. B. Prevention of simian acquired immune deficiency syndrome with a formalin-inactivated type D retrovirus vaccine. J. Virol 1986; 60: 431–435
   PubMed Web of Science ®Google Scholar
• Desrosiers R. C., Wyand M. S., Kodaraa X., Ringler D. J., Arthur L. O., Sehgal P. K., Letvin N. L., King N. W., Daniel M. D. Vaccine protection against simian immunodeficiency virus infection. Proc. Natl. Acad. Sci. USA 1989; 86: 6353–6357
   Google Scholar
• Murphy-Corb M., Martin L. N., Davison-Fairburn B., Montelaro R. C., Miller M., West M., Ohkawa S., Baskin B. G., Zhang J. -Y, Putney S. D., Allison A. C., Eppstein D. A. A formahn-inactivated whole SIV vaccine confers protection in macaques. Science 1989; 246: 1293–1297
   PubMed Web of Science ®Google Scholar
• Akerblom L., Villacres M., Lundin K., Ljunggren K., Morein B. Gpl60 iscoms: A candidate HIV vaccine. V International Conference on AIDS. June, 1989; 543, abstract #MCP10
   Google Scholar
• Putney S. D., Javaherian K., Profy A., Rusche J., Matthews X., Bolognesi D. Development of an HIV subunit vaccine. V International Conference on AIDS. June, 1989; 541, abstract #ThCO50
   Google Scholar
• Xhibodeau L., Flamand L., Oth D., Lachapelle L., Montagnier L. Comparison of immune responses in mice immunized with native HIV-2 envelope glycoprotein or corresponding immunosome. V International Conference on AIDS. June, 1989; 546, abstract #MCP29
   Google Scholar
• Hu S. -L., Kosowski S. G., Dalrymple J. M. Expression of AIDS virus envelope gene in recombinant vaccinia viruses. Nature 1986; 320: 537–540
   PubMed Web of Science ®Google Scholar
• Dolin R, Graham B., Greenberg S., Jacket C., Belshe R., Clements M., Fernie B., Stablein D., Smith G., Koff W. Safety and immunogenicity of HIV-1 recombinant gpl60 vaccine candidate in normal volunteers. V International Conference on AIDS. June, 1989; 538, abstract #XhC033
   Google Scholar
• Zagury D., Bernard J., Cheynier R., Desportes I., Leonard R., Fouchard M., Reveil B., Ittele D., Lurhuma Z., Mbayo K., Wane J., Salaun J -J., Goussard B., Dechazal L., Burny A., Nara R., Gallo R. C. A. group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS. Nature 1988; 332: 728–731
   PubMed Web of Science ®Google Scholar
• Collier A., Hu S. -L., Coombs R., Arditti D., Corey L. Clinical and virologic responses to a recombinant vaccinia HIV-1 gpl60 vaccine (HIVAC-le). V International Conference on AIDS. June, 1989; 543, abstract #MCP11
   Google Scholar
• Levy D. A., Rohbot J. M., Catalan E., et al. Phase II study of D.65I, an oral vaccine designed to prevent recurrences of vulvovaginal candidiasis. Vaccine 1989; 7: 337–340
   PubMed Web of Science ®Google Scholar
• Zykov M. P., Subbotina T. I. Modulation of humoral immune response to influenza vaccines by BCG. Acta. Virol 1985; 29: 403–409
   PubMed Web of Science ®Google Scholar
• Grab P. J., Joller-Jemelka H. I., Binsvanger H., Zornba K., Descocudres C., Fernex M. Interferon as an adjuvant for hepatitic B vaccination in non-and-low-responder populations. J. Clin. Microbiol 1984; 3: 195–198
   Google Scholar
• Jones W. R., Bradley J., Judd S. J., et al. Phase I clinical trial of a World Health Organization birth control vaccine. Lancet 1988; i: 1295–1298
   Google Scholar
• Cryz S. J., Jr, Sadoff J. C., Purer E. Immunization with Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine: effect of a booster dose on antibody levels in humans. Infect. Immun 1988; 56: 1829–1830
   PubMedGoogle Scholar
• Anderson P. W., Pichichero M. E., Stein E. C., et al. Effect of oligosaccharide chain length, exposed terminal group, and hapten loading on the antibody response of human adults and infants to vaccines consisting of Haemophilus influenzae type b capsular antigens N-terminally coupled to the diphtheria protein CRM 197. J. Immunol 1989; 142: 2464–2468
   PubMed Web of Science ®Google Scholar
• Zollinger W. D., Boslego J. W., Brandt E. E., et al. Safety and antigenicity studies of a polyvalent meningococcal protein-polysaccharide vaccine. Antoine Leeuwenhoek. J. Microbiol 1986; 52: 225–228
   Google Scholar
• Lowell G. H., Ballou W. R., Smith L. E., et al. Proteosome-lipopeptide vaccines: enhancement of immunogenicity for malaria CS peptides. Science 1988; 240: 800–802
   PubMed Web of Science ®Google Scholar